PARP inhibitors Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 26, 2022 Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan Aug 17, 2022 Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence Premium Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Aug 2, 2022 Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Apr 12, 2022 Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses Apr 11, 2022 UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study Apr 4, 2022 MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients Feb 17, 2022 Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response Feb 7, 2022 Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute Jan 31, 2022 Ideaya Options Exclusive Rights to PARG Inhibitor From CRUK, University of Manchester Jan 3, 2022 Allarity Therapeutics, Oncoheroes Biosciences Ink Pediatric Cancer Licensing Agreement Nov 30, 2021 AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer Nov 4, 2021 Repare Therapeutics' RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology Premium Nov 4, 2021 Burning Rock, Impact Therapeutics Ink Testing Deal for ATR Inhibitor Nov 3, 2021 Clovis' Q3 Rubraca Sales Drop 2 Percent Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
